<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342975</url>
  </required_header>
  <id_info>
    <org_study_id>18-000162</org_study_id>
    <nct_id>NCT04342975</nct_id>
  </id_info>
  <brief_title>Protection From Acute Kidney Injury (AKI) With Basis™ Treatment</brief_title>
  <official_title>A Phase II, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Efficacy of BASIS™ (Nicotinamide Riboside and Pterostilbene) Treatment for Kidney Protection in Patients Treated by Complex Aortic Aneurysm Repair and Aortic Arch Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Elysium Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-center, prospective, randomized, double-blinded, placebo-controlled
      phase II clinical trial to evaluate the efficacy of &quot;NAD+ supplementation&quot; with Basis™
      (Nicotinamide Riboside and Pterostilbene) in preventing acute kidney injury (AKI) in patients
      undergoing complex aortic aneurysm repair and open aortic arch reconstruction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is a single-center, prospective, randomized, double-blinded, placebo-controlled phase II clinical trial to evaluate the efficacy of &quot;NAD+ supplementation&quot; with Basis™ (Nicotinamide Riboside and Pterostilbene) in preventing acute kidney injury (AKI) in patients undergoing complex aortic aneurysm repair and open aortic arch reconstruction.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AKI</measure>
    <time_frame>6 months</time_frame>
    <description>The primary endpoint will be change in incidence of AKI measured by estimated glomerular filtration rate (eGFR) using the RIFLE criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>6 months</time_frame>
    <description>The secondary endpoint will be change in the incidence of myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel ischemia</measure>
    <time_frame>6 months</time_frame>
    <description>The secondary endpoint will be change in the incidence of bowel ischemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spinal cord injury</measure>
    <time_frame>6 months</time_frame>
    <description>The secondary endpoint will be change in the incidence of spinal cord injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nicotinamide Adenine Dinucleotide (NAD), Nicotinamide Mononucleotide (NMN), and Nicotinamide Riboside (NR)</measure>
    <time_frame>6 months</time_frame>
    <description>NAD, NMN, NR levels in peripheral blood mononuclear cells (PBMCs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue Inhibitor of Metalloproteinases 2 (TIMP2), Kidney Injury Molecule 1 (KIM-1), Insulin-like Growth Factor-binding Protein 7 (IGFBP7)</measure>
    <time_frame>6 months</time_frame>
    <description>TIMP2, KIM-1, IGFBP7 levels in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quinolinate and Tryptophan</measure>
    <time_frame>6 months</time_frame>
    <description>Quinolinate and Tryptophan levels in urine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">238</enrollment>
  <condition>AKI</condition>
  <arm_group>
    <arm_group_label>Basis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigational product, Basis™, contains a synthetic NR that is nature-identical to naturally-occurring NR, does not induce flushing or pruritus and has no effect on lipid levels. Also contains Pterostilbene (Ptero) that is a stilbenoid compound, characterized by two aromatic rings connected by a methylene bridge backbone, and it has two methoxy groups and one hydroxyl group extending from the aromatic rings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Correspondent placebo, a capsule not containing the active component.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotinamide Riboside + Pterostilbene</intervention_name>
    <description>It will be administered a total of 1000 mg/day of NR and 200 mg/day of Ptero in a regimen of 4 capsules of Basis™ (each capsule 125 mg of NR and 25 mg of Ptero) 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.</description>
    <arm_group_label>Basis</arm_group_label>
    <other_name>Basis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The correspondent placebo will be administered in a regimen of 4 capsules 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A patient may be included in the study if the following conditions are present:

               1. Male or female;

               2. Age &gt; 18 years old;

               3. Patients who match the criteria for indication of elective open aortic arch
                  replacement or repair:

                    1. Total arch;

                    2. Non-total arch;

               4. Patients who match the criteria for indication of elective complex aortic
                  aneurysm repair has to respect the following conditions:

                  a. Patients undergoing complex aortic aneurysm open reconstruction with a
                  suprarenal clamp; i. thoracoabdominal aortic aneurysms Crawford extent I to IV ;
                  ii. abdominal aortic aneurysms of juxtarenal, pararenal, or paravisceral type; b.
                  For endovascular approach: i. patients with pararenal or thoracoabdominal aortic
                  aneurysms Crawford extent I to IV and known stage III or IV of chronic kidney
                  disease (CKD); ii. patients with pararenal or thoracoabdominal aortic aneurysms
                  Crawford extent I to IV and solitary or single functioning kidney and known stage
                  III or IV CKD;

               5. Patients will be allowed to participate in concomitant endovascular aortic
                  stent-graft trials and prospective cohort studies as long as these do not involve
                  another investigational study drug.

        Exclusion Criteria:

          -  Patients must be excluded from the study if any of the following conditions are true:

        5.2.1 General Exclusion Criteria

          1. Unwilling to comply with the follow-up schedule;

          2. Inability or refusal to give informed consent by the patient or a legally authorized
             representative;

          3. Pregnant or breastfeeding;

          4. Subject who takes multivitamins containing vitamin B3 derivatives in a dose &gt; 200
             mg/day; 5.2.2 Clinical / Laboratory Exclusion Criteria

          5. Renal failure defined as eGFR&lt; 15 mL/min/1.73m2

          6. Patients in permanent Renal Replacement Therapy;

          7. Patients with chronic liver disease: Child-Pugh score class B and C; 5.2.3 Medication
             Exclusion Criteria

          8. Patients in chemotherapy scheme;

          9. Patients taking any immunosuppressant, except for corticosteroids;

         10. Patients taking any of these well-known P-glycoprotein substrates: digoxin,
             fexofenadine, indinavir, sirolimus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karina S Kanamori Mendes, MD</last_name>
    <phone>507-266-2173</phone>
    <email>mendes.karina@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karina S Kanamori Mendes, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 13, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Eduardo N. Chini</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>AKI</keyword>
  <keyword>open vascular surgery</keyword>
  <keyword>endovascular surgery</keyword>
  <keyword>aortic arch reconstruction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

